

Indigent Drug Program (IDP) Compliance

Policy

It is the policy of Central Florida Behavioral Health Network, Inc. (CFBHN) to comply with requirements of the IDP, and to support Network Service Providers' (NSPs) participation in the program.

Purpose

The purpose of this policy is to outline procedures and allowable costs in the administration of the IDP funded through the CFBHN.

Procedure

1. This program is authorized to assist adults with serious mental illnesses who meet clinical and financial guidelines for program participation.
 - A. To meet clinical criteria, individuals:
 - 1) Must be a member of a least one of the Department's priority populations; and
 - 2) Must not reside in a state mental health treatment facility or an inpatient community unit.
 - B. To meet financial eligibility criteria, individuals:
 - 1) Must have a net family income that is at or below 150% of federal poverty income guidelines;
 - 2) Must lack third-party insurance or other psychotropic medication funding sources. If individuals have third-party insurance for psychotropic medications but were temporarily denied benefits for these medications, they may receive IDP medications until such time as coverage or eligibility is re-established; and
 - 3) Must not participate in a program where other funding sources pay for psychotropic medication.
2. NSPs may use IDP funds to order psychotropic medications from a pharmacy of their choice.
3. Funds can also be used to pay dispensing fees for individuals who cannot afford them.
4. IDP providers are required by contract to actively participate in patient assistance programs (PAP) for medications offered by pharmaceutical manufacturers.
5. Using the EVNT (non-client specific file upload), NSPs should submit a service using the IDP OCA (MH076) with the Incidental Expense covered service (28) and the actual dollar amount divided by a rate of \$50 for the units.
6. Responsibilities of the Managing Entity are outlined in Guidance Document 13.

<p>Indigent Drug Program (IDP) Compliance</p> <p>Approval:  Linda McKinnon, President/Chief Executive Officer</p>	<p>Date Issued: <u>05/27/2019</u></p> <p>Last Revision: <u>06/10/2022</u></p> <p>Review Date: <u>06/10/2022</u></p>
---	---